Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients

Bibliography

• Hutchison AJ, Smith CP, Brenchley PEC. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011;7:578-89
   PubMed Web of Science ®Google Scholar
• Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007;18(3):875-85
   PubMed Web of Science ®Google Scholar
• Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008;19(6):1092-105
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16(6):1788-93
   PubMed Web of Science ®Google Scholar
• Phosphate binder use (national sample). US DOPPS Practice Monitor. 2013. Available from: www.dopps.org/DPM [Last accessed 5 November 2013]
   Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31(4):607-17
   PubMed Web of Science ®Google Scholar
• Block G, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67(3):1179-87
   PubMed Web of Science ®Google Scholar
• Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70(2):351-7
   PubMed Web of Science ®Google Scholar
• Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60(1):90-101
   PubMed Web of Science ®Google Scholar
• Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013;84(5):998-1008
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Liu J, Kestenbaum B. Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. Clin J Am Soc Nephrol 2011;6(1):175-83
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D; Independent Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7(3):487-93
   PubMed Web of Science ®Google Scholar
• Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009;75(9):890-7
   PubMed Web of Science ®Google Scholar
• Ketteler K, Wuthrich R, Floege J. Management of hyperphosphataemia in chronic kidney disease – challenges and solutions. Clin Kidney 2013;128-36
   PubMedGoogle Scholar
• Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39(4):695-701
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
   PubMed Web of Science ®Google Scholar
• Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009;20:381-7
   PubMed Web of Science ®Google Scholar
• Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009;20:397-404
   PubMed Web of Science ®Google Scholar
• Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15(7):1014-21
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438-41
   PubMed Web of Science ®Google Scholar
• London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18(9):1731-40
   PubMed Web of Science ®Google Scholar
• Verbeke F, Van Biesen W, Honkanen E; CORD Study Investigators. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011;6(1):153-9
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006;1(4):697-703
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5(3):519-30
   PubMed Web of Science ®Google Scholar
• Pohlmeier R, Vienken J. Phosphate removal and hemodialysis conditions. Kidney Int Suppl 2001;78:S190-4
   PubMedGoogle Scholar
• Floege J, Covic A, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014; Advance online publication
   Web of Science ®Google Scholar
• 2012. Annual report of the Dialysis Outcomes and Practice Patterns Study: haemodialysis data 1997-2011. Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA. Available from: www.dopps.org [Last accessed 1 December 2013]
   Google Scholar
• Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011(2):CD006023
   Google Scholar
• Savory J, Bertholf RL, Wills MR. Aluminium toxicity in chronic renal insufficiency. Clin Endocrinol Metab 1985;14(3):681-702
   PubMedGoogle Scholar
• Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996;45(2):111-19
   PubMed Web of Science ®Google Scholar
• Mudge DW, Johnson DW, Hawley CM, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 2011;12:20
   PubMed Web of Science ®Google Scholar
• Schaefer K, Umlauf E, von Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by administering cacitriol at night. Am J. Kidney Dis 1992;19:460-4
   PubMed Web of Science ®Google Scholar
• Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 2007;39(4):1209-16
   PubMed Web of Science ®Google Scholar
• Spasovski G, Vanholder R. Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride? Nephrol Dial Transplant. 2011;26(4):1442-3
   Google Scholar
• Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362(14):1312-24
   PubMed Web of Science ®Google Scholar
• Tzanakis IP, Papadaki AN, Wei M, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008;40(1):193-201
   PubMed Web of Science ®Google Scholar
• de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25(11):3707-17
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics: osvaren 435 mg/235 mg film-coated tablets. Fresnius Medical Care. 2011. Available from: www.medicines.org/emc [Last accessed 9 November 2013]
   Google Scholar
• Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96(10):2818-27
   PubMed Web of Science ®Google Scholar
• D’Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003(85):S73-8
   Google Scholar
• Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47(9):553-63
   PubMed Web of Science ®Google Scholar
• Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009;25(12):3021-8
   PubMed Web of Science ®Google Scholar
• Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12(8):1640-4
   PubMed Web of Science ®Google Scholar
• Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68(6):386-91
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 2009;24(1):278-85
   PubMed Web of Science ®Google Scholar
• Borzecki AM, Lee A, Wang SW, et al. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 2007;32(6):617-24
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Molony D, Bell C; Independent Study Investigators. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013;62(4):771-8
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72(9):1130-7
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bindren 92 - Public assessment report. 2012. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002377/human_med_001595.jsp&mid=WC0b01ac058001d124 [Last accessed 9 November 2013]
   Google Scholar
• Rosenbaum DP, Holmes-Farley SR, Mandeville WH, et al. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 1997;12:961-4
   PubMed Web of Science ®Google Scholar
• Kurihara S, Tsuruta Y and Akizawa T, Effect of MCI-196(colestilan) as a phosphate binder ohyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial. Transpl 2005;20:424-30
   PubMed Web of Science ®Google Scholar
• Locatelli F, Dimkovic N, Spasovski G. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant 2013;28(7):1874-88
   PubMed Web of Science ®Google Scholar
• Locatelli F, Dimkovic N, Pontoriero G, et al. Effect of colestilan on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo controlled study. Nephrol Dial Transplant 2010;25:574-81
   PubMed Web of Science ®Google Scholar
• Hertel JE, Nakajima S, Sano H, et al. Colestilan (MCI-196), a new calcium-free phosphate binder, is safe and effective in stage 5 CKD dialysis patients: phase 3, randomized, double-blind (DB), placebo (PBO)-controlled, multicenter study [abstract F-PO1862]. J Am Soc Nephrol 2010;21:538A
   Google Scholar
• Senatore F, Manning A, Nakajima S. A multi-centre,open-label, flexible dose, long-term safety study of colestilan in chronic kidney disease stage 5 subjects on dialysis with hyperphosphataemia. Nephrol Dial Transpl 2012;27(Suppl 2):ii52-4
   Google Scholar
• Locatelli F, Spasovski G, Dimkovic N, et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transplant 2013; published online 2 December 2013; doi: 10.1093/ndt/gft476
   Web of Science ®Google Scholar
• Wanner C, Varushchanka A, Apanasovich N, et al. A randomized, controlled trial of colestilan versus simvastatin for treatment of dyslipidemia in hemodialysis patients. Clin Nephrol 2014; In press
   PubMed Web of Science ®Google Scholar
• Dellanna F, Spasovski G, Wanner C, et al. LDL-cholesterol lowering in chronic kidney disease stage v dialysis patients with hyperphosphataemia: a comparison of colestilan (COL) and sevelamer (SEV). 2014; In press
   Google Scholar
• Kondo K, Kadowaki T. Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study. Diabetes Obes Metabol 2010;12:246-51
   PubMed Web of Science ®Google Scholar
• Staels B, Kuipers F. Bile acid sequestrants and the treatment of type-2 diabetes mellitus. Drugs 2007;67:1383-92
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance and diabetes by bile acid binding resin. Diabetes 2007;56:239-47
   PubMed Web of Science ®Google Scholar
• Duran-Sandoval D, Cariou B, Percevault F, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005;280:29971-9
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB. The “forgotten” bile acid sequestrants: is now a good time to remember? Am J Ther 2007;14:567-80
   PubMed Web of Science ®Google Scholar
• Garg J, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis. Arthritis Rheum 2005;52:290-5
   PubMed Web of Science ®Google Scholar
• Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med 2009;48:415-20
   PubMed Web of Science ®Google Scholar
• Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 2011;6(10):2470-7
   PubMed Web of Science ®Google Scholar
• Feng S, Jiang L, Shi Y, et al. Uric acid levels and all-cause mortality in peritoneal dialysis patients. Kidney Blood Press Res 2013;37:181-9
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-52
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68(4):1815-24
   PubMed Web of Science ®Google Scholar
• Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20(8):1653-61
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics: bindRen 1 g film-coated tablets. Mitsubish. 2013. Available from: www.medicines.org/emc [Last accessed 9 November 2013]
   Google Scholar
• Summary of product characteristics: Renvela 800 mg film coated tablets. Sanofi. 2011. Available from: www.medicines.org/emc [Last accessed 9 November 2013]
   Google Scholar
• Grinfeld J, Inaba A, Hutchison AJ. Update and critical appraisal of sevelamer in the management of chronic renal failure. Open Access J Urol 2010;2:161-70
   PubMedGoogle Scholar
• Wanner C. Chronic kidney disease and statin therapy: to treat or not to treat? Eur Heart J Open Access publication 2013
   Google Scholar